(Total Views: 554)
Posted On: 03/04/2022 7:45:16 AM
Post# of 90
INOVIO PHARMACEUTICALS: A LONG SHOT INVESTMENT!
$INO
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced that it is pausing enrolment for an ongoing late-stage study evaluating its lead COVID-19 vaccine candidate INO-4800, as labs tests show that the candidate had significantly lower level of antibodies against the Omicron variant. The move is likely to delay the interim efficacy data from the trial, which was expected to be announced in the first half of 2022.
Read on to find more!
https://www.aviseanalytics.com/inovio-pharmac...nvestment/
$INO
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced that it is pausing enrolment for an ongoing late-stage study evaluating its lead COVID-19 vaccine candidate INO-4800, as labs tests show that the candidate had significantly lower level of antibodies against the Omicron variant. The move is likely to delay the interim efficacy data from the trial, which was expected to be announced in the first half of 2022.
Read on to find more!
https://www.aviseanalytics.com/inovio-pharmac...nvestment/
(0)
(0)
